



Dedicated To Life

February 9, 2024

Listing Department
BSE LIMITED
P J Towers, Dalal Street,
Mumbai-400 001

Code: 532321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, C/1, Block G,
Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: ZYDUSLIFE

Re: **Investor Presentation**

Dear Sir,

Please find attached the Investor Presentation on the unaudited financial results for the quarter / nine months ended on December 31, 2023.

Please find the same in order.

Thanking you,

Yours faithfully,
For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI
COMPANY SECRETARY

Encl.: As above





Zydus Lifesciences Limited

Earnings Presentation: Q3 FY24

9th February, 2024

- *THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY"). The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.*
- *By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.*
- *The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.*

Revenues from Operations

Rs. 45,052 mn
 ↑ 6% YoY

R&D

Rs. 3,146 mn
 7.0% of revenues


EBITDA & Margin %

Rs. 11,024 mn
 24.5% of revenues
 ↑ 15% YoY

Net Profit

Rs. 7,896 mn
 ↑ 27% YoY

Business-wise Sales Break-up (Rs. mn) and YoY Growth



Highlights of Q3 FY24


- Total revenues grew **6% YoY**, led by **India** and **EM& EU formulations** businesses.
- **India formulations** business delivered **strong double digit growth** on the back of **healthy volume growth** and **new product launches**.
- **Leading** brands of **Consumer Wellness** business viz. **Glucon-D, EverYuth Scrub & Peel off** and **Nycil** gained market share during the quarter.
- **US base** business displayed **robust momentum** with **sustained volume expansion** on a sequential basis **well supported** by **new launches**.
- **EM & EU formulations** business **sustained** the **growth momentum** and delivered **double digit growth** for **yet another quarter**.
- EBITDA margin stood at **24.5%, up 200 bps YoY**.
- Capex (organic) for the quarter: Rs. 2,137 mn.
- Net debt to EBITDA: (-) 0.3x (at 31-Dec'23) vs (-) 0.14x (at 31-Mar'23)

Key Board Meeting Updates


- The Board approved **buy-back** of upto **Rs. 6000 mn** at **Rs. 1005 per equity share** (25% premium to closing share price of 8th February, 2024).

Key Financial Metrics (1/2)


Total Revenues (Rs. mn)




Total R&D (Rs. mn) and % to Revenues



Gross Profit (Rs. mn) and Gross Margin %




EBITDA (Rs. mn) and EBITDA Margin %




Key Financial Metrics (2/2)


PAT ex. Exceptional (Rs. mn)




Organic Capex (Rs. mn)



Net Debt/ EBITDA




Net Working Capital* (Rs. mn)




*Net working capital includes Inventory, Trade receivables and Trade payables.

Strong volume uptake drove the growth

India Formulations Sales (Rs. mn)



Q3 FY24 Revenue Contribution



Q3 FY24 Gr.

YoY

15.9%

QoQ

7.0%

Brand building - a key growth driver

of Brands

1000+

8

500 to 1000


21

250 to 500

33

Brand Value (Rs. Mn)*

Therapy-wise Break-up*




Highlights for the quarter

- Branded business grew **faster** with **17% YoY growth**. **Key pillar brands** and **innovation portfolio** posted **strong volume growth** and drove the overall growth.
- Gained rank** in **cardiac** and **anti-infective** therapies. Registered **improvement in market share** in **anti-diabetic** and **anti-infective** therapies.
- On the Super Specialty front,
 - Retained **leadership** position in the **nephrology** segment.
 - In the **oncology** segment, continued to grow at the **fastest pace**.
- Chronic** portfolio **grew faster** than the market with **12% growth*** vs. **IPM growth of 11%***. **Share of chronic** therapies in overall portfolio **went up by 136 bps*** in **CY23** to **41%***.


*Source: IQVIA MAT December 23

Category leading brands continued to gain market share

Consumer Wellness Sales (Rs. mn)



Q3 FY24 Revenue Contribution



Q3 FY24 Gr.

YoY

-3.5%

QoQ

-8.7%

Highlights for the quarter

- FMCG sector witnessed **subdued demand** similar to previous quarter as **expected buoyancy** in demand from **rural** parts of the country **continued to lag**.
- Personal care segment, which comprises of **Nycil®** and **EverYuth®** brands, registered **yet another** quarter of **strong growth**.
- Gross margins **continued** the **upward journey** with an **improvement** both on a **sequential** and **YoY** basis.

Key brands continued to hold dominant market share

Brand Name



Market Share#

60.0%

35.1%

96.0%

6.2%

44.4%

79.5%

4.3%

Facial
Cleansing *

Scrub


Peel
Off

#Source: Nielsen and IQVIA MAT December 2023 report


* Facial cleansing segment includes Face wash, Scrub and Peel-off.

Base business displayed sustained volume growth

US Formulations Sales (Rs. mn)



Q3 FY24 Revenue Contribution



Q3 FY24 Gr.

YoY


-4.3%

QoQ


-1.2%

Continued investment to build the generics pipeline


ANDA filings and approvals - Q3 FY24



ANDA filings and approvals - Apr - Dec 23



ANDA filings and approvals - Cumulative




Highlights for the quarter

- **Profitability** of **base** business **improved** on the back of **sustained volume expansion** and **new product launches** made over the last 12 months.
- Launched **11 new products**.
New launches include launch of **first 505(b)(2)** product viz. **Zituvio™** and **2 transdermal** products.
- **Filed 12 ANDAs** and received **final approval** for **6 new ANDAs**.

^ includes 1 tentative approval during Apr - Dec 23 period and 21 tentative approvals on a cumulative basis.

All key markets continued to display strong momentum

EM & EU Formulations Sales (Rs. mn)



Q3 FY24 Gr.


YoY

30.5%

QoQ

9.6%

Q3 FY24 Revenue Contribution



Highlights for the quarter

- All **major** markets of **Asia Pacific** region and **Africa** registered **robust double-digit growth**.
- Demand** scenario remained **strong** in **Europe**. In **Mexico**, the business **continued to grow in double digits**.
- Focusing on **scaling up** operations in the **UK** by leveraging the **global R&D portfolio** of **differentiated** and **niche generics** as well as **specialty products**.

NCE: Saroglitazar Magnesium

- Expect to complete recruitment of patients for Phase II(b)/ III clinical trials for PBC indication for the US market during the current quarter.
- Completed hepatic impairment studies in cirrhotic cholestatic patients and published the results of the study in CPDD.

NCE: ZYIL1 (NLRP3 inhibitor)

- Received permission from the USFDA to initiate Phase II clinical trials in patients with Parkinson's disease. The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the molecule in patients with Parkinson's disease.
- Phase II clinical trials are going on in India in patients with ALS indication. ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset.

NCE: ZY19489 (Anti-malarial)

- Completed Phase II clinical trials and submitted the protocol to DCGI to initiate Phase III clinical trials.

Biotech R&D

- The pipeline continues to advance with two mAbs awaiting marketing approvals in India.
- Two other products including one mAb are currently undergoing Phase III clinical trials in India.

Specialty Initiatives

- Completed asset transfer of CUTX-101, a Copper Histidinate product candidate for treatment of Menkes Disease from Cyprium Therapeutics.
- Acquired worldwide proprietary rights and the USFDA documents pertaining to CUTX-101 under the agreement.
- Rolling NDA submission of CUTX-101 is going on at present which is expected to be over during the current calendar year.

Zydus at a Glance

~\$2.15
bn
Global Revenues¹

5th
Largest generic Co. in US
in terms of prescription³

7
R&D Centers
For NCE, APIs, Gx formulations,
Biosimilars and Vaccines

>40%
Revenues from India
Geography (Formulations
and wellness) in FY23

**Among
Top 3**
In ~55% of product
families marketed in US⁴

1st
Approved product for
NASH in India - (Bilypsa[®] -
Saroglitazar)

\$9.8
bn
Market Capitalization²

8
Brands among Top
300 in India⁵

1st
OSD formulation for anemia
associated with CKD –
Oxemia[™] (Desidustat)

36
Mfg. sites having
capabilities across
dosage forms

>25 K
Zydans globally incl.
>1400 scientists (R&D)

22
Biosimilars in portfolio
(incl. 3 ADCs), launched
13 products in India

1. In FY23, assuming exchange rate of Rs. 80.4 per USD
2. As on 8th February, 2024, exchange rate of Rs. 83 per USD
3. IQVIA MAT December 2023 TRx

4. IQVIA MAT December 2023 TRx
5. As per IQVIA MAT December 2023

Consolidated Financial Performance (reported)

Rs. mn	Q3 FY24	Q3 FY23	YoY gr.	Q2 FY24	QoQ gr.	9M FY24	9M FY23	YoY gr.
Total Income from Ops.	45,052	42,571	5.8%	43,688	3.1%	1,40,136	1,22,268	14.6%
Gross Contribution (GC)	30,367	27,466	10.6%	28,950	4.9%	93,969	76,127	23.4%
Gross Margin %	67.4%	64.5%		66.3%		67.1%	62.3%	
Employee benefits expenses *	7,354	6,282	17.1%	6,767	8.7%	20,645	18,320	12.7%
R&D expenses	3,146	3,446	-8.7%	3,195	-1.5%	9,580	8,822	8.6%
Other operating expenses *	9,050	9,231	-2.0%	8,349	8.4%	26,964	26,371	2.2%
Net [gain]/loss on foreign currency transactions	-206	-1,053	80.4%	-822	74.9%	-757	-3,429	77.9%
EBITDA	11,024	9,560	15.3%	11,461	-3.8%	37,538	26,043	44.1%
EBITDA Margin %	24.5%	22.5%		26.2%		26.8%	21.3%	
Other Income	377	385	-2.1%	540	-30.2%	1,277	1,488	-14.2%
Finance cost	198	328	-39.6%	87	127.6%	466	1,022	-54.4%
Depreciation and amortization	1,948	1,816	7.3%	1,842	5.8%	5,588	5,441	2.7%
PBT before exceptional items	9,255	7,801	18.6%	10,072	-8.1%	32,761	21,068	55.5%
Exceptional Expenses/ (Incomes)	-	-		-		142	29	389.7%
Profit before Tax	9,255	7,801	18.6%	10,072	-8.1%	32,619	21,039	55.0%
Tax expenses	2,138	1,952	9.5%	2,264	-5.6%	6,563	4,506	45.7%
Share of profit from JVs	564	459	22.9%	234	141.0%	1,013	828	22.3%
Profit/(loss) from discontinued ops.	218	4		-10		198	-24	925.0%
Minority Interest	3	83	-96.4%	25	-88.0%	495	700	-29.3%
Reported Net Profit	7,896	6,229	26.8%	8,007	-1.4%	26,772	16,637	60.9%

* Excludes Research related expenses

Details of Exchange Rate Fluctuations

Rs. mn	Q3 FY24	Q3 FY23	YoY gr. %	9M FY24	9M FY23	YoY gr. %
A. On operating transactions (above EBITDA line)	-228	-1,097	79.2%	-807	-3,639	77.8%
a. Included in COGS	-22	-44	51%	-50	-210	76.4%
b. Part of other operating expenses (shown separately)	-206	-1,053		-757	-3,429	
B. On other income	-	-17	100.0%	-	-253	100.0%
C. On foreign currency borrowings (part of finance cost)				4	1	300.0%
Total Exchange Rate Fluctuations ('+' = loss, '-' = gain)	-228	-1,114	79.6%	-803	-3,891	79.4%

Thank you

For any queries, please contact
Arvind Bothra
Arvind.Bothra@zyduslife.com
+91-22-62711905



For more information, please visit:
www.zyduslife.com



www.linkedin.com/company/zyduslife



Registered Office:

Zydus Corporate Park, Scheme No. 63, Survey No. 536,
Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,
Sarkhej-Gandhinagar Highway,
Ahmedabad – 382 481
Gujarat, India